Home Featured Page 177

Featured

Latest

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Psychedelic Bulletin: Tensions Rise among Oregon’s Psilocybin Advisory Board; Colleges Team...

PT300 – Dr. Richard C. Schwartz – Vital Psychedelic Conversations

HPPD and Flashbacks: Everything You Need To Know – And What...

Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the...

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic...

PT299 – Ed Prideaux – HPPD (Hallucinogen Persisting Perception Disorder): A...

Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead...

Psychedelic Research Bulletin: February 2022

PT298 – Michael Sapiro, PsyD – Vital Psychedelic Conversations

1...176177178...301 Page 177 of 301

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

CLOSING RECEPTION Travis Gillan’s Revelator

Psychedelic Bulletin: Tensions Rise among Oregon’s Psilocybin Advisory Board; Colleges Team...

PT300 – Dr. Richard C. Schwartz – Vital Psychedelic Conversations

HPPD and Flashbacks: Everything You Need To Know – And What...

Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the...

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

Numinus Adds Ayahuasca & San Pedro to Federal License for Psychedelic...

PT299 – Ed Prideaux – HPPD (Hallucinogen Persisting Perception Disorder): A...

Psychedelic Bulletin: The Cost-Effectiveness of MDMA for PTSD; The Challenges Ahead...

Psychedelic Research Bulletin: February 2022

PT298 – Michael Sapiro, PsyD – Vital Psychedelic Conversations

EDITOR PICKS

Review: Colorado Psychedelic Cup 2025

Dr Ros Watts – Building Communities and Connection

The Psychedelic News Feed: October 27 – November 02, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY